Malaria Drug Resistance Is Becoming Alarmingly Sophisticated, Study Finds

Microorganisms’ capacity to evolve at extraordinary speed gives them an advantage in a world where microbes prey on one another.

When one organism develops a defence, another can swiftly evolve a means of bypassing or defeating it. Scientists call this an evolutionary arms race, one of nature’s most potent evolutionary pressures.

This formidable capacity for rapid evolution becomes a human problem when microbes direct it against the medicines used to treat life-threatening infections.

Malaria drug resistance is growing more complex

For the most harmful malaria pathogen, drug resistance is taking on an increasingly worrying complexity.

A new genetic analysis of Plasmodium falciparum - the parasite behind the deadliest type of malaria - suggests it is accumulating adaptations associated with resistance to a broad range of drug treatments.

"These findings underscore the dual challenge of persistent resistance to discontinued drugs and rising threats to current frontline therapies," write infectious-disease researchers led by Alemayehu Letebo of Ethiopia’s Armauer Hansen Research Institute, Leen N. Vanheer of the UK’s London School of Hygiene and Tropical Medicine, and colleagues.

Their results are described in Nature Microbiology.

Malaria ranks among the world’s most lethal infectious diseases, affecting hundreds of millions of people annually and killing hundreds of thousands - predominantly children younger than 5 and, largely, people in Africa.

Although the illness can be prevented and cured, researchers are continually trying to keep ahead of the parasite. Over the past 70 years, P. falciparum has evolved resistance to nearly every antimalarial treatment developed, including artemisinin, one of the most important malaria medicines and a drug discovered during the 1970s.

Partial artemisinin resistance was initially detected in South-East Asia more than 15 years ago; it has since been reported at several sites across Africa.

Yet resistance is not simply a switch that turns on abruptly, then turns off once it is unnecessary.

It may involve numerous genetic alterations. Some emerge in response to medicines currently being used, while others could persist as leftovers from past battles with treatments that have been retired.

Map showing sample-collection locations, malaria intensity and overlap between malaria parasites. (Letebo et al., Nat. Microbiol. , 2026)

Ethiopia’s P. falciparum resistance patterns

The situation in Ethiopia is particularly complicated. Chloroquine ceased to work against P. falciparum many years ago. The first-line treatment is now the combined medicine artemether-lumefantrine, which pairs the artemisinin drug artemether with lumefantrine.

However, P. falciparum is not the sole parasite able to cause malaria. P. vivax, another parasite that generally causes a less deadly malaria form, remains vulnerable to chloroquine and circulates across many of the same locations as P. falciparum.

The researchers set out to establish whether these overlapping drug pressures are influencing P. falciparum evolution, and whether the parasite carries multiple drug-resistance markers in potentially concerning combinations.

They sequenced drug-resistance genes in 605 P. falciparum samples taken from 15 Ethiopian districts between 2019 and 2023. These areas differed in malaria intensity and in the degree of overlap with P. vivax.

Graphs showing the prevalence, geographical distribution and co-occurrence of resistance mutations. (Letebo et al., Nat. Microbiol. , 2026)

The results showed that chloroquine-resistance markers are still widespread in the parasite, despite chloroquine having been removed from the P. falciparum treatment toolkit decades earlier. A genetic pattern of resistance to this medicine occurred in 61.2 percent of 492 successfully classified samples.

The team suggests that chloroquine’s continued use for treating P. vivax malaria could be helping resistance persist in P. falciparum. Geographical patterns back up this interpretation, although further research is required.

Markers linked with resistance to sulfadoxine-pyrimethamine also remained prevalent, appearing in 42.8 percent of 453 samples, despite this treatment not having been used against malaria in Ethiopia since 2005.

Meanwhile, markers of resistance to treatments in current use are spreading. The primary marker of partial artemisinin resistance was present in 10 percent of 572 samples.

Other markers were less frequent but were commonly concentrated in particular regions. In one district, partial artemisinin resistance was as high as 48.6 percent.

Most troubling, however, was the frequent appearance of these resistance markers together. For instance, parasites with chloroquine-resistance markers had more than threefold greater odds of carrying markers of partial artemisinin resistance as well.

A genetic pattern associated with lower sensitivity to lumefantrine was also identified in 93 percent of 483 classified samples.

This points to the potential for a double blow of resistance. It is important, however, that the researchers assessed genetic markers rather than whether artemether-lumefantrine itself is becoming less effective.

A patchwork of malaria parasite populations

The clearest finding is that Ethiopia does not face a single uniform drug-resistance issue. Instead, it contains a patchwork of parasite populations with differing combinations of mutations.

As a result, efforts to tackle malaria and treatment resistance cannot rely on a universal, one-size-fits-all strategy.

This does not indicate that Ethiopia’s present approach to malaria has ceased to be effective. But the researchers say it should be regarded as a warning sign.

Related: Drug-Resistant Bacteria May Be Jumping Between Pets And Humans, Scientists Warn

The parasite is not following one predictable evolutionary route, and identical drug pressures may not influence it in the same manner everywhere.

Health officials now have an opportunity to adapt surveillance strategies so they better match the evolving and complex landscape of drug resistance in malaria parasites.

"Taken together, Ethiopia's distinct P. falciparum cluster, marked geographic heterogeneity in resistance markers and correlation with species composition highlight the need for region-specific control strategies," the researchers write.

"Integrated surveillance systems that monitor both P. falciparum and P. vivax, coupled with whole-genome sequencing and longitudinal data linked to clinical outcomes, will be essential to track resistance evolution and guide tailored interventions."

The paper was published in Nature Microbiology.

This article was fact-checked and edited by Fiona MacDonald. Although we take pride in our process, we are only human. If you notice an error, please let us know.